Bayer

Last updated January 31, 2026

432

Innovation Areas

13,147

Inventors

104

Collaborations

Benzimidazole chymase inhibitors: BayerRecent Research Landscape

Unregulated enzymatic activity and protein misfolding drive vascular and neurodegenerative damage. These specific chemical inhibitors and chaperones stabilize protein folding and thrombi resolution to prevent irreversible tissue loss.

What technical problems is Bayer addressing in Benzimidazole chymase inhibitors?

Pathological tissue remodeling

(37)evidences

Uncontrolled blood clot formation leads to life-threatening cardiopulmonary and thromboembolic events. Preventing these specific failure modes in vascular patency reduces mortality and morbidity in cardiovascular disease.

Inadequate therapeutic response prediction

(32)evidences

Inadequate immune response activation and poor drug stability. Overcoming these limitations enables effective treatment of complex inflammatory or oncological pathologies.